A detailed history of E Fund Management Co., Ltd. transactions in Dynavax Technologies Corp stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 16,856 shares of DVAX stock, worth $216,599. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,856
Previous 18,929 10.95%
Holding current value
$216,599
Previous $212,000 11.79%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.05 - $11.61 $20,833 - $24,067
-2,073 Reduced 10.95%
16,856 $187,000
Q2 2024

Aug 12, 2024

SELL
$10.73 - $12.58 $150,767 - $176,761
-14,051 Reduced 42.6%
18,929 $212,000
Q1 2024

May 13, 2024

BUY
$11.7 - $14.98 $46,378 - $59,380
3,964 Added 13.66%
32,980 $409,000
Q4 2023

Feb 06, 2024

BUY
$13.09 - $14.98 $59,323 - $67,889
4,532 Added 18.51%
29,016 $405,000
Q3 2023

Nov 13, 2023

BUY
$12.64 - $14.99 $19,276 - $22,859
1,525 Added 6.64%
24,484 $362,000
Q2 2023

Aug 11, 2023

SELL
$9.85 - $13.17 $76,416 - $102,172
-7,758 Reduced 25.26%
22,959 $297,000
Q1 2023

May 11, 2023

SELL
$9.44 - $11.88 $29,981 - $37,730
-3,176 Reduced 9.37%
30,717 $301,000
Q4 2022

Feb 14, 2023

SELL
$10.27 - $13.29 $71,838 - $92,963
-6,995 Reduced 17.11%
33,893 $361,000
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $104,950 - $184,323
10,569 Added 34.86%
40,888 $427,000
Q2 2022

Aug 15, 2022

BUY
$7.45 - $12.83 $20,904 - $36,000
2,806 Added 10.2%
30,319 $382,000
Q1 2022

May 12, 2022

BUY
$9.75 - $14.44 $142,028 - $210,347
14,567 Added 112.52%
27,513 $298,000
Q4 2021

Feb 11, 2022

BUY
$13.17 - $20.94 $170,498 - $271,089
12,946 New
12,946 $182,000
Q3 2021

Nov 12, 2021

SELL
$9.16 - $19.83 $132,581 - $287,019
-14,474 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$4.57 - $11.18 $66,146 - $161,819
14,474 New
14,474 $142,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.63B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.